GlassScriptPhysician profile
Michael N Katzoff
NPI 1558304485
$37,487.68
in general payments reported to CMS, 2019-2025
26 companies · $450 in 2025
The $450 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $8,875 · 2021: $6,610 · 2022: $772 · 2023: $209 · 2024: $211 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $520 · Consulting Fee: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $520.48 |
| Consulting Fee | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $33,791.95 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $815.90 | 2019-2025 | |
| Insmed, INC. | $549.33 | 2019-2024 | Arikayce |
| Astrazeneca Pharmaceuticals LP | $373.06 | 2019-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $256.38 | 2023-2025 | Lumryz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.91 | 2019-2022 | |
| Grifols USA, LLC | $231.15 | 2019-2022 | |
| Inspire Medical Systems, INC. | $225.07 | 2022-2024 | Inspire |
| Abbott Laboratories | $158.46 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Genzyme Corporation | $136.81 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $135.19 | 2019-2022 | |
| Pulmonx Corporation | $86.08 | 2019-2020 | |
| Mylan Specialty L.P. | $81.42 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $65.66 | 2023 | Quviviq |
| Harmony Biosciences LLC | $64.28 | 2020-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $48.53 | 2019-2024 | |
| Electromed, INC. | $41.76 | 2021 | |
| Genentech USA, INC. | $33.97 | 2019 | |
| Shire North American Group INC | $30.48 | 2019 | |
| Advanced Respiratory, INC | $20.58 | 2019 | |
| Gilead Sciences, INC. | $16.90 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.90 | 2021 | |
| Phadia US INC. | $16.73 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.05 | 2022 | |
| Biogen, INC. | $12.95 | 2020 | |
| Eisai INC. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Katzoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.